Sclerostin Antibody Dosing Regimen for Bone Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bone disorders, such as osteoporosis, often fail to provide a rapid and sustained increase in bone formation and density, leading to increased fragility and susceptibility to fractures, particularly in older women.
Innovation Solution
Administering a high initial loading dose of sclerostin antibody followed by lower doses, and altering dosing frequency or incorporating dosing holidays, to promote rapid bone formation and maintain increased bone density.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If a high initial loading dose of sclerostin antibody is administered, then rapid bone formation is achieved, but the complexity of the dosing regimen increases
Solution Approach 1:
The dosing regimen is segmented into distinct phases: an initial loading dose phase followed by a maintenance dosing phase. This segmentation allows the high dose to be administered only when needed to achieve rapid bone formation, while subsequent lower doses maintain the effect, thereby reducing overall regimen complexity while preserving the speed benefit.
Solution Approach 2:
The high initial loading dose serves as a preliminary action that rapidly achieves the desired therapeutic effect of bone formation. By administering the full effect upfront, the subsequent maintenance doses only need to sustain this effect, simplifying the overall dosing strategy while ensuring rapid initial bone formation.
2Reliability
If dosing frequency is increased to maintain bone density, then bone health improvement is enhanced, but treatment complexity and patient burden increase
Solution Approach 1:
The dosing frequency is made dynamic rather than static. The regimen starts with more frequent dosing to establish and maintain bone density, then transitions to less frequent maintenance dosing. This dynamic adjustment optimizes bone density maintenance while improving patient convenience by reducing the long-term dosing burden.
Solution Approach 2:
The treatment employs periodic action with alternating phases of intensive dosing and maintenance dosing. By structuring the regimen as periodic cycles rather than continuous frequent dosing, the patent achieves reliable bone density maintenance while significantly improving ease of operation and reducing patient burden during maintenance phases.
3Duration of action of stationary object
If continuous dosing is administered, then sustained bone formation is achieved, but the risk of adverse effects increases
Solution Approach 1:
The patent applies partial action by administering the full therapeutic effect through a high initial loading dose, then using only sufficient (not excessive) maintenance doses to sustain the effect. This approach achieves sustained bone formation while minimizing the cumulative exposure that could lead to adverse effects, thereby reducing the harmful factors associated with continuous full-dose administration.
Solution Approach 2:
The preliminary high-dose action achieves the maximum bone formation effect upfront, creating a reservoir of therapeutic benefit. Subsequent lower maintenance doses only need to sustain this effect rather than repeatedly achieving it, thereby maintaining the duration of action while reducing the cumulative dose and associated adverse effects.
Data Source
AI summary
The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.